

**Bristol Myers Squibb Shareholder Meeting Question**  
**Ethan Peck, Associate, Free Enterprise Project**  
**National Center for Public Policy Research, May 3, 2022**

As part of its “Diversity & Inclusion” program, Bristol Myers Squibb (BMS) made a commitment to spend \$1 billion with “diverse” suppliers over the next 5 years. Why is BMS favoring businesses and organizations solely based on the skin pigmentation of their leadership? Do you think that communities whom you deem as “diverse” are unable to succeed on their own merit?

And furthermore, why should shareholders trust your moral judgment in the reallocation of \$1 billion worth of their funds when BMS is currently in an ongoing \$1 billion lawsuit over its participation in the Guatemala Syphilis Experiment?

*Contact: Judy Kent at (703) 477-7476 or [JKent@nationalcenter.org](mailto:JKent@nationalcenter.org)  
and David W. Almasi at (703) 568-4727 or [DAlmasi@nationalcenter.org](mailto:DAlmasi@nationalcenter.org)  
National Center for Public Policy Research  
20 F Street, NW, Suite 700, Washington, DC 20001  
[www.nationalcenter.org](http://www.nationalcenter.org) • @NationalCenter • @FreeEntProject*